Order Entry
Canada
ContactUsLinkComponent
Human Recombinant IL17 (from E. coli)
Human Recombinant IL17 (from E. coli)
Catalog # 75788-754
Supplier:  Prosci
CAS Number:  
Human Recombinant IL17 (from E. coli)
Catalog # 75788-754
Supplier:  Prosci
Supplier Number:  91-015
CAS Number:  

Specifications

  • Protein/peptide type:
    Recombinant
  • Source:
    E. coli
  • Species:
    Human
  • Size:
    0.05 mg
  • Storage conditions:
    Lyophilized protein should be stored at −20 °C, though stable at room temperature for 3 weeks. Reconstituted protein solution can be stored at 4-7 °C for 2-7 days. Aliquots of reconstituted samples are stable at −20 °C for 3 months.
  • Endotoxin content:
    <0.1 ng/ug (1 IEU/ug) as determined by LAL test.
  • Biological activity:
    ED50 is approximately 2 ng/ml as determined by the dose-dependent induction of IL-6 in primary human foreskin fibroblasts.
    Specific Activity of 5 x 105 IU/mg.
  • Protein synonyms:
    IL-17|IL17|CTLA8|IL17A|IL-17A|Cytotoxic T-Lymphocyte-Associated Antigen 8|CTLA-8|Interleukin-17A
  • Protein/peptide name:
    IL17
  • Purity:
    > 95% as determined by reducing SDS-PAGE
  • Molecular weight:
    15.26 kD
  • Sequence:
    Ile20-Ala155
  • Formulation:
    Lyophilized from a 0.2 um filtered solution of 20mM PB, pH 7.4. Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100 ug/ml. Dissolve the Lyophilized protein in ddH2O. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
  • Tested applications:
    Bioassay
  • Cat. no.:
    75788-754
  • Supplier No.:
    91-015

Specifications

About this item

Interleukin-17 is a potent pro-inflammatory cytokine produced by activated memory T cells. There are at least six members of the IL-17 family in humans and in mice. As IL-17 shares properties with IL-1 and TNF-alpha, it may induce joint inflammation and bone and cartilage destruction. This cytokine is found in synovial fluids of patients with rheumatoid arthritis, and produced by rheumatoid arthritis synovium. It increases IL-6 production, induces collagen degradation and decreases collagen synthesis by synovium and cartilage and proteoglycan synthesis in cartilage. IL-17 is also able to increase bone destruction and reduce its formation. Blocking of interleukin-17 with specific inhibitors provides a protective inhibition of cartilage and bone degradation.

This recombinant protein can be used for biological assays. For research use only.